Nautilus Biotechnology reports Q2 2024 net loss of $18M, operating expenses up 9% YoY

Nautilus Biotechnology, Inc.

2024-Q2 EPS reported -$0.29

Net loss of $18.0M in Q2 2024 vs $15.8M in Q2 2023.
Operating expenses of $20.8M, up $1.8M or 9% from $19.0M a year ago.
Cash, equivalents, and investments of $232.9M as of June 30, 2024.
Expense increase driven by higher headcount to support product development.
Company continues development of single-molecule proteome analysis platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.